Literature DB >> 18757410

EBV is necessary for proliferation of dually infected primary effusion lymphoma cells.

Amanda A Mack1, Bill Sugden.   

Abstract

Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution to these cancers is unclear. We found that dominant-negative derivatives of EBNA1 inhibited EBV-positive PEL cells from forming colonies. Those rare PEL cells that proliferated after expression of the dominant-negative derivatives usually expressed these derivatives at low or undetectable levels and continued to maintain their EBV genomes. Those proliferating cells expressing higher levels of the derivatives expressed mutant derivatives that could not bind DNA. These findings indicate that EBV is required to sustain proliferation, as measured by colony formation of dually infected PEL cells. The dominant-negative derivatives of EBNA1 had no effect on the colony-forming ability of five EBV-negative, KSHV-negative hematopoietic cell lines. Surprisingly, they did inhibit the colony-forming ability of EBV-negative, KSHV-positive PEL cells. The small fraction of cells that continued to proliferate expressed only mutants of the EBNA1 derivatives that could no longer bind DNA. These findings indicate that the site-specific DNA-binding activity of EBNA1 or its derivatives when expressed efficiently in EBV-negative, KSHV-positive PEL cells inhibits their colony formation possibly through their binding to the KSHV genome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757410      PMCID: PMC2587434          DOI: 10.1158/0008-5472.CAN-08-0627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells.

Authors:  L Sternås; T Middleton; B Sugden
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

2.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus.

Authors:  D M Knowles; G Inghirami; A Ubriaco; R Dalla-Favera
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

4.  Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells.

Authors:  A Krithivas; D B Young; G Liao; D Greene; S D Hayward
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

6.  Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression.

Authors:  Pankaj Trivedi; Kumi Takazawa; Claudia Zompetta; Laura Cuomo; Elena Anastasiadou; Antonino Carbone; Stefania Uccini; Filippo Belardelli; Kenzo Takada; Luigi Frati; Alberto Faggioni
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

7.  The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy.

Authors:  D Y Lee; B Sugden
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

8.  Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.

Authors:  Gregory Kennedy; Jun Komano; Bill Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-05       Impact factor: 11.205

9.  Primary lymphomatous effusions in AIDS: a morphological, immunophenotypic, and molecular study.

Authors:  I Green; E Espiritu; M Ladanyi; R Chaponda; R Wieczorek; L Gallo; H Feiner
Journal:  Mod Pathol       Date:  1995-01       Impact factor: 7.842

10.  Diagnosis of malignant lymphoma in effusions from patients with AIDS by gene rearrangement.

Authors:  A E Walts; I P Shintaku; J W Said
Journal:  Am J Clin Pathol       Date:  1990-08       Impact factor: 2.493

View more
  18 in total

1.  Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.

Authors:  Italo Tempera; Alessandra De Leo; Andrew V Kossenkov; Matteo Cesaroni; Hui Song; Noor Dawany; Louise Showe; Fang Lu; Priyankara Wikramasinghe; Paul M Lieberman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.

Authors:  Rachele Bigi; Justin T Landis; Hyowon An; Carolina Caro-Vegas; Nancy Raab-Traub; Dirk P Dittmer
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-14       Impact factor: 11.205

3.  Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Authors:  Debasmita Roy; Sang-Hoon Sin; Blossom Damania; Dirk P Dittmer
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

4.  Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus.

Authors:  Zhiqiang Qin; Lu Dai; Mark G Slomiany; Bryan P Toole; Chris Parsons
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 5.  Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas.

Authors:  Sangmin Kang; Jinjong Myoung
Journal:  J Microbiol       Date:  2017-04-29       Impact factor: 3.422

6.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

7.  Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).

Authors:  Fang Lu; Priyankara Wikramasinghe; Julie Norseen; Kevin Tsai; Pu Wang; Louise Showe; Ramana V Davuluri; Paul M Lieberman
Journal:  Virol J       Date:  2010-10-07       Impact factor: 4.099

8.  Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma.

Authors:  Hiroki Goto; Yuki Kojima; Hirokazu Nagai; Seiji Okada
Journal:  Int J Hematol       Date:  2013-04-21       Impact factor: 2.490

9.  Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes.

Authors:  Lindsay R Dresang; David T Vereide; Bill Sugden
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

10.  Identification of properties of the Kaposi's sarcoma-associated herpesvirus latent origin of replication that are essential for the efficient establishment and maintenance of intact plasmids.

Authors:  Prabha Shrestha; Bill Sugden
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.